New scan could reveal how well immunotherapy is working

NCT ID NCT06534190

Recruiting now Diagnosis Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special imaging agent (89Zr-DF-Crefmirlimab) that helps PET scans show immune cells called CD8 T-cells inside tumors. About 30 adults with advanced solid tumors will receive this agent before and during standard immunotherapy (anti-PD-1). The goal is to see if the scan can track immune activity and predict treatment response, which could help doctors personalize cancer care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOLID TUMOR

Contacts and locations

Locations

University Medical Center Groningen
RECRUITING

Groningen, 9713 GZ, Netherlands
University of Cambridge
NOT_YET_RECRUITING

Cambridge, CB2 1TN, United Kingdom
VUMC
RECRUITING

Amsterdam, 1081 HV, Netherlands
Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron Institute Research (VHIR)
NOT_YET_RECRUITING

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.